New insulin analog provides mealtime glucose control
The FDA recently approved insulin glulisine [DNA origin](Apidra, Aventis Pharmaceuticals) for the control of hyperglycemia in adult patients with diabetes mellitus. According to the manufacturer, insulin glulisine should be used in regimens that include a longer-acting insulin or basal insulin analog. Aventis recently announced that it will delay the launch of insulin glulisine until after the approval of its OptiClick pen delivery device
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Related Content
